medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2016, Number 2

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2016; 14 (2)

Basal cell carcinoma. Treatment with intralesional alfa 2b interferon

Vega GLG

Language: Spanish
References: 26
Page: 102-107
PDF size: 292.86 Kb.


ABSTRACT

Background: basal cell carcinoma is the most common cancer and surgery is the treatment of choice. There are nonsurgical options, such as intralesional alfa 2b interferon.
Objetive: the aim was to establish the safety and efficacy of iINFα2b and report if the topography and morphology of the lesion influence in the clinical response.
Methods: we studied 78 patients at Dermatology section in a Hospital Vasco de Quiroga, issste, in the city of Morelia, Michoacán. All patients included with either primary or recurrent tumor, and treated with 2 million of iu of INFα2b intralesional three times a week, with a total dosis of 18 000 000 ui.
Results: the global positive response was 84.6%, and the clinical types, nodular and morpheaform, had a better response and good aesthetic results.
Conclusions: infα2b is a safe and efficacious alternative treatment of basal cell carcinoma, especially the nodular and morpheaform types.


REFERENCES

  1. Rubin, A.J., Chen, E.H. y Ratner, D., “Basal cell carcinoma”, N Eng J Med, 2005, 353 (21): 2262-2269.

  2. “Guía de práctica clínica, prevención, diagnóstico y tratamiento del carcinoma basocelular”, México, Secretaría de Salud, 2013.

  3. Dessinoti, C., Antonio, C., Katsanaba, A. y Stratigos, A.J., “Basal cell carcinoma: what’s new under the sun, Photochem Photobiol, 2010, 86: 481-491.

  4. Madan, V., Hoban, R., Strange, A. et al., “Genetics and risk factors for basal cell carcinoma”, Br J Dermatol, 2006, 154: 5-7.

  5. Elmet, C., Cather, M. y Hui, X., “Photoimmunology”, Dermatol Clin, 2014, 32: 277-290.

  6. Gregory, A.D. y Houghto, A.M., “Tumor-associated neutrophils: new targets for cancer therapy”, Cancer Res, 2011, 71 (7): 2411-2416.

  7. Lacour, J.P., “Carcinogenesis of basal cell carcinoma: genetic and molecular mechanism”, Br J Dermatol, 2002, 146: 17-19.

  8. Walker, P. y Hill, D., “Surgical treatment of basal cell carcinoma using standard postoperative histological assessment”, Australas J Dermatol, 2006, 47: 1-12.

  9. Smith, V. y Walton, S., “Treatment of facial basal cell carcinoma: a review”, J Skin Cancer, 2011, 380871.

  10. Griffiths, R.W., Suvarna, S.K. y Stone, J., “Basal cell carcinoma histological clearance margins: an analysis of 1 539 conventionally excised tumors. Wider still and deeper?”, J Plast Reconstr Aesthet Surg, 2007, 60: 41-47.

  11. Kwasniak, L.A. y García-Zuazaga, J., “Basal cell carcinoma: evidence based, medicine and review of treatment modalities”, Int J Dermatol, 2011, 50: 645-658.

  12. Lear, J.T., “Evidence-based treatment for low-risk basal cell carcinoma”, Lancet Oncol, 2014, 15 (1): 12-13.

  13. Greenway, H.T., Cornell, R.C., Tanner, D.J. et al., “Treatment of basal cell carcinoma with intralesional interferon”, J Am Acad Dermatol, 1986, 15: 437-443.

  14. Chimenti, S., Peris, K., Di Cristofaro, S., Fargnoli, M.C. y Torlone, G., “Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma”, Dermatology, 1995, 190: 214-217.

  15. Edwards, L., Tucker, S.B., Perednia, D., Simles, K.A. et al., “The effect of an intralesional sustained-release formulation of interferon alfa 2B on basal cell carcinomas”, Arch Dermatol, 1990, 126: 1029-1032.

  16. Cornell, R.C., Greenway, H.T., Tucker, S.B. et al., “Intralesional interferon therapy for basal cell carcinoma”, J Am Acad Dermatol, 1990, 23: 694-700.

  17. Buechner, S.A., “Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression”, J Am Acad Dermatol, 1991, 24: 731-734.

  18. Alpsoy, E., Yilmas, E., Bas ¸aran, E. y Yazar, S., “Comparison of the effects of intralesional interferon alfa 2a, 2b and the combinatios of 2a and 2b in the treatment of basal cell carcinoma”, J Dermatol, 1996, 23: 394-396.

  19. Fenton, S., Kennedy, S. y Moriarty, P., “The role of interferon alpha 2b as an adjunctive treatment in the management of aggressive basal cell carcinoma of the eyelids”, Acta Ophthalmol Scand, 2002, 80 (6): 674-675.

  20. Kim, K.H., Yavel, R.M., Gross, V.L. y Brody, N., “Intralesional interferon alfa 2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited”, Dermatol Surg, 2004, 30: 115-120.

  21. Lee, S., Selva, D., Huilgol, S.C. et al., “Pharmacological treatment for basal cell carcinoma”, Drugs, 2007, 67 (6): 915-934.

  22. Good, L.M., Miller, M.D. y High, W.A., “Intralesional agents in the management of cutaneous malignancy: a review”, J Am Acad Dermatol, 2011, 64: 413-422.

  23. Morris, A.G., “Interferons”, Immunology, 1988, (S1): 43-45.

  24. Ransohoff, R.M., “Cellular responses to interferons and other cytokines: the jak-stat paradigm”, N Engl J Med, 1998, 338 (9): 616-618.

  25. Farkas, À. y Kemèny, L., “Interferon α in the generation of monocyte- derived dendritic cells: recent advances and implications for dermatology”, Br J Dermatol, 2011, 165: 247-254.

  26. Buechner, S.A., Wernli, M., Harr, T., Itin, P. y Erb, P., “Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by cd95 (Apo-1/Fas)-cd95 ligand-induced suicide”, J Clin Invest, 1997, 100 (11): 2691-2696.




2020     |     www.medigraphic.com